

> **PRESS RELEASE / 3 May 2016**

Coloplast delivers H1 result in line with expectations

Revenue was up by 7% to DKK 7,256 million in H1 2015/16. EBIT was also up by 7% to DKK 2,361 million for an EBIT margin of 33%. The results are in line with the company's guidance.

A growing demand for Coloplast's ostomy care products among European users produced strong sales and 8% organic growth for the Ostomy Care business in the first six months of the 2015/16 financial year.

"More and more users are choosing our stoma bags and accessories, allowing us to outgrow the market. We've also just launched one of our future growth drivers, the Sensura Mio Convex, in fifteen countries, and user feedback has been highly satisfactory," said Coloplast CEO Lars Rasmussen.

In the regional markets, Coloplast is generating solid sales growth in Europe, and especially Coloplast UK, its largest subsidiary, is a strong contributor to growth in the European business. Charter, Coloplast's own distribution company in the UK, is also winning market shares.

"UK is currently the stand-out market in Europe, however, countries like France and the Netherlands are also delivering good results, steering our European market in the right direction," says Mr Rasmussen.

The Wound & Skin Care business delivered 9% organic growth in the reporting period, and Urology Care sales were up by 8%.

Coloplast's Continence Care business grew by 4%, the weak growth rate being mainly due to amended distributor contracts in the US market. Sales are expected to normalise in the second half of the financial year.

Coloplast maintains its guidance for the 2015/2016 financial year of 7–8% organic revenue growth at constant exchange rates. With GBP and USD weakened against DKK, the company now expects 6–7% growth in DKK instead of previously 7%. The EBIT margin is expected to be 33–34% at constant exchange rates and about 33% in DKK.

For more on the Q2 2015/16 interim report, go to www.coloplast.com/investor.

Press enquiries

Maria Lindeberg
Senior media relations manager
Tel. +45 4911 3095
dkmalg@coloplast.com

Investors and analysts

Ian Christensen
Vice President, Investor
Relations
Tel. +45 4911 1301
dkisec@coloplast.com

Financial highlights and key ratios (DKKm)	2015/2016 6M	2014/2015 6M	Change
Revenue	7,256	6,748	8%
EBIT	2,361	2,213	7%
EBIT margin	33%	33%	-

Sales performance by business area	DKKm 6M 2015/2016	DKKm 6M 2014/2015	Organic growth	Reported growth
Ostomy Care	2,898	2,699	8%	7%
Continence Care	2,557	2,430	4%	5%
Urology Care	741	661	8%	12%
Wound & Skin Care	1,060	958	9%	11%
Revenue	7,256	6,748	7%	8%